All Posts Tagged With: "AMLN"

(PRX) Par Pharmaceuticals Companies to be Aquired by TPG

Yet another acquisition agreement was recently announced in the pharma sector. US based specialty pharmaceutical company Par Pharmaceuticals Companies Inc. (PRX) entered into an agreement with an affiliate of leading global private...

21Aug2012 | | Comments Off | Continued

(BMY) Bristol-Myers Squibb Earnings Preview

Biopharmaceutical giant  Bristol-Myers Squibb Company (BMY) is all set to unveil  its second quarter 2012 results before the start of trading on July 25, 2012. The Zacks Consensus Estimate for the second quarter of 2012 is 50 cents...

13Aug2012 | | Comments Off | Continued

(PFE) Pharma and Biotech Stock Outlook – August 2012 – Industry Outlook

The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer’s (PFE) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major...

10Aug2012 | | Comments Off | Continued

(BMY) Bristol-Myers Squibb Barely Misses Expectations

Bristol-Myers Squibb Company’s (BMY) second quarter 2012 earnings (excluding special items) of 48 cents per share fell short of the Zacks Consensus Estimate of 49 cents by a penny. Second quarter earnings declined 14% from the year-ago...

25Jul2012 | | Comments Off | Continued

(LLY) Eli Lilly and Company GLP-1 Agonist Delivers

Eli Lilly and Company (LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study. Dulaglutide is a glucagon-like peptide 1...

28May2012 | | Comments Off | Continued

(AAPL) Guide to the 25 Cheapest ETFs – ETF News And Commentary

There are several factors that influence the decision of selecting an ETF for investment. Such factors include the past performance, holdings, sector exposure and concentration. Beyond these examples, expenses can also play an important role in the decision making process as well. The expense...

18May2012 | | Comments Off | Continued

(ALKS) Risk-Reward Balanced at Alkermes

We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00. Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter...

7Mar2012 | | Comments Off | Continued

(AMLN) Amylin Pharmaceuticals Posts Lower Loss

Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses...

25Oct2011 | | 0 comments | Continued

(AAPL) A Busy Week Ahead – Earnings Preview

Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500. Thus, by the end of the week we will have a very good idea...

17Oct2011 | | 0 comments | Continued

(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes

Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early...

19Sep2011 | | 0 comments | Continued

(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares

We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous...

1Sep2011 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs

Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year...

27Jul2011 | | 0 comments | Continued

(NVO) Novo Nordisk Presents Late Stage Degludec Data

Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi...

5Jul2011 | | 0 comments | Continued

(ALKS) Alkermes Presents Encouraging Data

Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer...

1Jul2011 | | 0 comments | Continued

(NVO) Novo Nordisk Presents Diabetes Study Data

Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like Peptide- 1 (GLP-1) analogue...

29Jun2011 | | 0 comments | Continued

(ALKS) Alkermes Evenly Poised

We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop...

24Jun2011 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals, Partners Eli Lilly and Alkermes Learn Bydureon Gains EU Approval

Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS),...

22Jun2011 | | 0 comments | Continued

(LLY) Eli Lilly Launches Type II Diabetes Treatment Tradjenta

Eli Lilly and Company (LLY) and partner Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that their type II diabetes treatment, Tradjenta (linagliptin) is now available in pharmacies across the US. Tradjenta, which has...

17Jun2011 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates

Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline in revenues, year-over-year...

20Apr2011 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals, Eli Lilly, and Alkermes Get Positive Opinion for Bydureon

Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS),...

18Apr2011 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals Analyst Reports Neutral on Shares

We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). The company reported a net loss of $0.94 per share in 2010, narrower than the Zacks Consensus Estimate of $1.26 and the year-ago loss of $1.20....

29Mar2011 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals Releases Disappointing Data

Shares of Amylin Pharmaceuticals, Inc. (AMLN) lost more than 25% when the company released disappointing data on Bydureon (exenatide once-weekly) from a head-to-head study. Bydureon failed to achieve its primary endpoint of non-inferiority...

28Mar2011 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals Analyst Maintains Neutral

We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). Amylin reported a net loss of $0.31 per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the...

20Dec2010 | | 0 comments | Continued

(ALKS) Alkermes 2010 Second Quarter Revenues Rise – View Lowered

Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was a loss of 15 cents per...

24Nov2010 | | 0 comments | Continued

(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook

With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product...

15Nov2010 | | 0 comments | Continued

(AMLN) Amylin Pharmaceuticals Reports Wider Loss

Amylin Pharmaceuticals (AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents. Lower revenues resulted in the...

12Nov2010 | | 0 comments | Continued

(ALKS) Alkermes’ Vivitrol Earns US Food and Drug Administration Clearance

Alkermes Inc. (ALKS) received a boost when the US Food and Drug Administration (FDA) cleared its drug Vivitrol (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence after opioid...

17Oct2010 | | 0 comments | Continued

(BMY) Bristol-Myers Squibb’s Pipeline Advances

Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind, study (n=814)....

15Oct2010 | | 0 comments | Continued

(BMY) Bristol-Myers Squibb Trial Presents Encouraging Data

Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind, study...

3Oct2010 | | 0 comments | Continued

(BMY) Bristol-Myers Squibb Company Diabetes Drug Candidate Encourages

Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, international, randomized, parallel-group, double-blind, placebo-controlled...

21Sep2010 | | 0 comments | Continued